Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 5, No 1 (2013) Dopamine dysregulation syndrome in Parkinson’s disease Abstract  similar documents
A V Nikitina, Natalia Vladimirovna Fedorova
"... receiving high doses of dopaminergic drugs. In the patients with DDS concurrent with punding ..."
 
Vol 6, No 1 (2014) Apathy in Parkinson's disease patients Abstract  similar documents
M. R. Nodel
"... pathy in Parkinson's disease (PD) patients is one of the least studied manifestations of a broad ..."
 
Vol 6, No 4 (2014) Dopaminergic deficiency syndrome in the picture of severe brain injury in the presence of protracted depression of consciousness Abstract  similar documents
M. V. Chelyapina, E. V. Sharova, O. S. Zaitsev
"... Objective: to determine the clinical and electroencephalographic (EEG) signs of dopaminergic ..."
 
Vol 1, No 2 (2009) RESTLESS LEGS SYNDROME Abstract  similar documents
Dmitriy Valer'evich Artem'ev, Dmitriy Valeryevich Artemyev
"... legs syndrome, polyneuropathy, paresthesia, dopaminergic insufficiency. Dmitriy Valeryevich Artemyev ..."
 
Vol 3, No 1 (2011) Sleep disorders in Parkinson's disease Abstract  similar documents
Marina Romanovna Nodel', Marina Romanovna Nodel
"... of Parkinson's disease (PD). Objective: to specify the clinical features of sleep disorders in patients with PD ..."
 
Vol 4, No 2 (2012) Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease Abstract  similar documents
S N Illarioshkin
"... Dopaminergic stimulation with levodopa, a biological precursor of dopamine precursor, and dopamine ..."
 
Vol 6, No 3 (2014) Current therapy for Parkinson's disease Abstract  similar documents
A. V. Obukhova
"... The main goal of therapy for Parkinson's disease (PD) is to correct dopamine deficiency ..."
 
Vol 11, No 3 (2019) The use of vortioxetine for the correction of depression in Parkinson's disease: an example of clinical cases Abstract  similar documents
I. V. Miliukhina
"... in the dose of dopaminergic drugs and to the development of complications. Difficulties in choosing ..."
 
Vol 4, No 1 (2012) Sustained-release pramipexole in the treatment of Parkinson’s disease Abstract  similar documents
Natalia Vladimirovna Fedorova
"... for dopaminergic deficiency in Parkinson’s disease (PD). Since 1996, pramipexole has been used to treat early ..."
 
Vol 5, No 1 (2013) Practical aspects of the use of extended-release ropinirole (requip modutab) in the treatment of Parkinson’s disease Abstract  similar documents
Oleg Semenovich Levin, V K Datiyeva
"... receptor agonist (DRAs), which has been widely used to treat Parkinson’s disease (PD) in foreign countries ..."
 
Vol 8, No 4 (2016) HYPERSOMNIA AND CIRCADIAN DISTURBANCES IN PARKINSON’S DISEASE Abstract  similar documents
M. R. Nodel
"... studied symptoms of Parkinson’s disease (PD). It manifests as constant excessive sleepiness during the day ..."
 
Vol 5, No 2 (2013) Current possibilities of therapy for sleep disorders in Parkinson’s disease Abstract  similar documents
Marina Romanovna Nodel
"... and awakening disorders in patients with Parkinson's disease (PD). It covers the current views of the role ..."
 
Vol 3, No 3 (2011) Neuropsychiatrie disorders in Parkinson's disease and their correction with the MAO-B inhibitor rasagiline (Azilect®) Abstract  similar documents
M R Nodel
"... Parkinson's disease (PD) is a multisystemic neurodegenerative disease with a broad spectrum ..."
 
Vol 6, No 4 (2014) Nondrug therapy in the combination rehabilitation of patients with Parkinson’s disease Abstract  similar documents
V. L. Golubev, A. B. Kamakinova
"... Non-drug rehabilitation in Parkinson’s disease (PD) has recently attracted the increasing ..."
 
Vol 2, No 4 (2010) Depression in Parkinson's disease Abstract  similar documents
Marina Romanovna Nodel', Marina Romanovna Nodel
"... Parkinson's disease (PD) is a multisystemic neurodegenerative disease with a wide spectrum ..."
 
Vol 7, No 3 (2015) Experience in using levodopa-benserazide Abstract  similar documents
Elena Anatolyevna Katunina, Yu. N. Bezdolnyi, E. A. Malykhina, N. V. Titova
"... Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper ..."
 
Vol 9, No 1 (2017) The genetic basis of Parkinson's disease Abstract  similar documents
A. A. Tappakhov, T. E. Popova, T. Ya. Nikolaeva, P. I. Gurieva, N. A. Shnaider, M. M. Petrova, M. R. Sapronova
"... Parkinson's disease (PD) is a multifactorial disease that develops in the presence of both genetic ..."
 
Vol 1, No 2 (2009) NERVOUS AND MENTAL DISORDERS OF PARKINSON'S DISEASE Abstract  similar documents
Marina Romanovna Nodel', N N Yakhno, Marina Romanovna Nodel, N N Yakhno
"... Parkinson's disease (PD) is a multisystemic neurodegenerative disease involving different mediator ..."
 
Vol 5, No 2 (2013) Emergence from protracted unconsciousness due to severe diffuse axonal brain injury: clinical observation and literature review Abstract  similar documents
Evgenia Vladimirovna Aleksandrova, O S Zaitsev, M V Chelyapina, E V Sharova, E Yu Sokolova, V M Gavrilov, N E Zakharova, Yu V Vorobyev, V D Tenediyeva, V A Shurkhai, E M Troshina, A A Potapov
"... for the efficiency of use of not only direct stimulants of dopaminergic transmission, but also drugs with indirect ..."
 
Vol 5, No 2 (2013) The clinical picture of early-stage Parkinson’s disease. errors in the diagnosis of different forms Abstract  similar documents
E N Gubanova, Natalia Vladimirovna Fedorova
"... The paper describes the clinical picture of Parkinson’s disease (PD), by indicating its stages ..."
 
Vol 5, No 3 (2013) The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease Abstract  similar documents
Marina Romanovna Nodel
"... patch in Parkinson's disease (PD) and discusses the results of clinical trials of Rotigotine in early ..."
 
Vol 3, No 4 (2011) Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole Abstract  similar documents
Marina Romanovna Nodel
"... Fatigability is a common nonmotor symptom in Parkinson's disease (PD), which worsens quality ..."
 
Vol 7, No 4 (2015) Some aspects of treatment for cognitive impairments. Cyticolin: pharmacological characteristics, possible benefits, aspects of use Abstract  similar documents
N. V. Trofimova, I. S. Preobrazhenskaya
"... ; neuroprotective effect; sirtuins; Alzheimer’s disease; Parkinson’s disease. Contact: Irina Sergeevna ..."
 
Vol 4, No 1 (2012) Sleep and awakening disorders in Parkinson’s disease: comprehensive approach to therapy Abstract  similar documents
Marina Romanovna Nodel
"... and awakening disorders in patients with Parkinson’s disease (PD). It covers the current views of the role ..."
 
Vol 4, No 3 (2012) Clinical experience with requip modutab Abstract  similar documents
Denis Valeryevich Zakharov, V A Mikhailov
"... of therapy for extensive-stage Parkinson’s disease (PD) and to correct motor fluctuations and drug-induced ..."
 
Vol 9, No 3 (2017) Screening for non-motor symptoms in Parkinson's disease using the NMSQuest scale Abstract  similar documents
A. A. Tappakhov, T. E. Popova, T. Ya. Nikolaeva, N. A. Schnaider, M. M. Petrova
"... The clinical picture of Parkinson's disease (PD) includes a wide range of non-motor symptoms (NMS ..."
 
Vol 5, No 2 (2013) Neuropsychological syndromes in patients with Parkinson’s disease after deep electric stimulation of pallidar complex structures Abstract  similar documents
Yu V Mikadze, Irina Igorevna Titkova, A O Gushcha, V M Tyurnikov
"... The paper provides the results of neuropsychological examinations in 10 patients with Parkinson’s ..."
 
Vol 10, No 4 (2018) Nighttime sleep disorders in patients with daytime sleepiness in Parkinson s disease Abstract  similar documents
M. R. Nodel, K. V. Shevtsova, G. V. Kovrov, N. N. Yakhno
"... Daytime sleepiness is one of the clinically significant non-motor manifestations of Parkinson ..."
 
Vol 2, No 3 (2010) Treatment of parkinson's disease ata young age Abstract  similar documents
Dmitry Valeryevich Artemyev
"... and middle-aged patients. It is stressed that early-onset Parkinson's disease (PD) shows a number ..."
 
Vol 6, No 4 (2014) The epidemiological, clinical, and genetic characteristics of Parkinson’s disease (in case of Zheleznogorsk) Abstract  similar documents
M. R. Sapronova, N. A. Shnaider
"... Parkinson’s disease (PD) is the second most common human neurodegenerative disorder. Genetically ..."
 
Vol 3, No 1 (2011) Heart rhythm variability analysis in patients with Levy body dementiaand in those with Parkinson's disease Abstract  similar documents
I G Tishkova, Irina Sergeevna Preobrazhenskaya, I G Tishkova, Irina Sergeyevna Preobrazhenskaya
"... ) and Parkinson's disease (PD). Objective: to analyze autonomic provision of cardiac performance in patients ..."
 
Vol 9, No 1 (2017) The clinical features, diagnosis, and treatment of cognitive impairments in Parkinson's disease Abstract  similar documents
G. N. Akhmadeeva, R. V. Magzhanov, G. N. Tayupova, A. R. Baitimerov
"... with Parkinson's disease (PD) and gives their characteristics and epidemiology, the specific features ..."
 
Vol 10, No 4 (2018) Chemoreactome analysis of tolperisone, tizanidine, and baclofen molecules: anticholinergic, antispasmodic, and analgesic mechanisms of action Abstract  similar documents
I. Yu. Torshin, O. A. Gromova, L. V. Stakhovskaya, V. A. Semenov
"... , dopaminergic, GABAergic neurotransmission. Each of the studied molecules was established to exert dose ..."
 
Vol 10, No 3 (2018) Effect of indapamide/perindopril fixed-dose combination on 24-hour blood pressure and cognitive functions in treatment-naive middle-aged patients with essential arterial hypertension Abstract  similar documents
T. M. Ostroumova, V. A. Parfenov, O. D. Ostroumova, E. V. Borisova
"... Objective: to investigate the effect of indapamide/perindopril fixed-dose combination (FC) on 24 ..."
 
Vol 1, No 1 (2009) THERAPY FOR EPILEPSY IN MIDDLE-AGED AND ELDERLY PATIENTS Abstract  similar documents
P N Vlasov, O V Andreeva, P N Vlasov, O V Andreyeva
"... , a frequent combination with concomitant mental and somatic diseases, and a relative efficacy of small-dose ..."
 
Vol 4, No 1 (2012) Association of the dopamine receptor (DRD4, DAT) gene polymorphisms with vital exhaustion in an open population among 25—64-year-old men (Novosibirsk): Epidemiological study according to the WHO MONICA-psychosocial program Abstract  similar documents
Valery Vasilyevich Gafarov, M I Voyevoda, E A Gromova, V N Maksimov, A V Gafarova, I V Gagulin, N S Yudin, T M Mishakova
"... Ассоциация полиморфизма генов дофаминергической системы (DRD4, DAT) с жизненным истощением в ..."
 
Vol 9, No 4 (2017) Neuropsychological pattern of Parkinson's disease Abstract  similar documents
A. A. Tappakhov, T. E. Popova, T. Ya. Nikolaeva, N. A. Schnaider, M. M. Petrova, M. R. Sapronova
"... The review deals with the problem of neuropsychological disorders in Parkinson's disease (PD), one ..."
 
Online-first Features of pathogenesis and clinical manifestation of Parkinson's disease developed from essential tremor Abstract  similar documents
A. V. Kudrevatykh, I. V. Miliukhina
"... In last decades, there is evidence of the relationship of Parkinson's disease (PD) and essential ..."
 
Vol 11, No 2 (2019) Pathogenesis, clinical features, and treatments of depression in Parkinson's disease Abstract  similar documents
I. V. Milyukhina
"... Depression is the most common non-motor manifestation of Parkinson's disease (PD), which ..."
 
Vol 2, No 3 (2010) Chronic pain Abstract  similar documents
Mikhail Lvovich Kukushkin
"... the schedule in individual doses. ..."
 
Vol 9, No 1 (2017) Comparison of the efficacy of the multimodal serotonergic antidepressants trazodone and vortioxetine in the treatment of patients with endogenous depression: A meta-analysis of double-blind randomized placebo-controlled trials Abstract  similar documents
D. S. Danilov
"... in Group 1: a) therapy with trazodone at an average dose of about 300 mg/day significantly more frequently ..."
 
Vol 9, No 4 (2017) Sleep disorders in Parkinson’s disease: approaches to treatment and prevention Abstract  similar documents
M. R. Nodel, G. V. Kovrov
"... Nocturnal sleep disorders are one of the most important non-motor manifestations of Parkinson’s ..."
 
Vol 3, No 3 (2011) Use of amelotex to treat patients with acute musculoskeletal pain in the back and grade 1 essential hypertension Abstract  similar documents
E V Podchufarova, N N Yakhno
"... of the safety and efficacy of amelotex (meloxicam injectable dosage form) in an intramuscular dose of 15 mg/day ..."
 
Vol 4, No 1 (2012) Experience in using sulpiride in non-psychotic endogenous depressive-hypochondriacal disorders Abstract  similar documents
Nina Arkadyevna Tyuvina, V. V. Balabanova, E M Goncharova
"... in an initial dose of50—100 mg/day; the dose was, if required, increased up to 400—600 mg/day. Results. After 2 ..."
 
Vol 4, No 1 (2012) New possibilities in the prevention of stroke in atrial fibrillation Abstract  similar documents
Vladimir Anatolyevich Parfenov, S V Verbitskaya
"... the efficacy of the new thrombin inhibitor dabigatran (pradax) in a dose of 150 or 110 mg twice daily ..."
 
Vol 4, No 2S (2012): Сognitive and other neuropsychiatric disorders Cognitive and neuropsychiatric disorders in extrapyramidal diseases Abstract  similar documents
O. S. Levin, M. A. Anikin, E. E. Vasenina
"... of Parkinson’s disease or Huntington’s disease in persons who are predisposed to these diseases. Moreover ..."
 
Vol 8, No 2 (2016) Chronic valproic acid intoxication in epileptology: diagnosis and treatment Abstract  similar documents
N. A. Shnaider, D. V. Dmitrenko
"... are described in the use of both high and average therapeutic doses of VA preparations in patients ..."
 
Vol 11, No 3 (2019) The features of the pathogenesis and clinical picture of Parkinson's disease that has developed in essential tremor Abstract  similar documents
A. V. Kudrevatykh, I. V. Miliukhina
"... In the past decades, there has been evidence on the relationship between Parkinson's disease (PD ..."
 
Vol 3, No 4 (2011) Ketorolac in clinical practice Abstract  similar documents
Andrei Evgenyevich Karateev
"... permits reductions in the dose of opioids and in the risk of their adverse reactions ..."
 
Vol 4, No 2 (2012) The efficacy and tolerability of paroxetine (adepress), an antidepressant from a group of selective serotonin reuptake inhibitors, in psychoautonomic syndrome within anxiety-depressive disorders Abstract  similar documents
T G Voznesenskaya, N M Fokina
"... (paroxetine) was used in a dose of 10—20 mg/day for 8 weeks. Adverse reactions were observed in one-third ..."
 
1 - 50 of 497 Items 1 2 3 4 5 6 7 8 9 10 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)